Compare Adaptive Biotechnologies Corp (ADPT) vs Medtronic PLC (MDT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Medtronic PLC — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Medtronic PLC trades at $82.37 (market cap $107.31B). The key difference: Medtronic PLC is far larger — about 32.2× Adaptive Biotechnologies Corp's market cap, and Medtronic PLC pays a 3.44% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MDT | |
|---|---|---|
Market Cap | $3.33B | $107.31B |
Sector | Health | Health |
52-Week High | $22.37 | $105.35 |
52-Week Low | $10.24 | $73.75 |
Enterprise Value | $3.19B | $126.05B |
Dividend Yield | — | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Medtronic (MDT) trades at $83.83, up 0.77% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company shows improving fundamentals with 2025 revenue of $33.54B and net income of $4.66B, supported by a 13.2% net margin. Recent acquisition of Scientia Vascular enhances its neurovascular portfolio, while analyst consensus remains strongly positive with a $98.77 price target.
MDT presents a compelling investment case with steady growth, a 3.5% dividend yield, and undervaluation relative to analyst targets. Key risks include rising debt levels and margin pressures from tariffs. The stock's current position near support levels offers a potential entry point for long-term investors seeking healthcare sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
